We have completed analysis of over 250 lung cancer samples by a high- resolution genome profiling method developed here at Cold Spring Harbor Laboratory (CSHL). We found twelve major recurrent amplicons, most of which contain known driver genes such as MYC or KRAS2, and three others that do not, including the second most frequent amplicon which is located at 14q13. Our first specific aim is to perform comprehensive functional evaluation of all three candidate driver genes within this frequently amplified region at 14q13. This comprehensive functional evaluation will utilize both gain-of-function transformation assays and loss-of-function assays using new RNA interference technology, developed here at CSHL, that silences gene expression in vitro and in vivo. We have preliminary data that indicates that all three genes, each encoding a different transcription factors, synergistically promote the proliferation of lung epithelial cells. In addition to functional analysis, we have formed collaborations to address the potential diagnostic and prognostic significance of 14q13 amplification. The other two novel frequent amplicons contain several candidate genes. To address the difficulty inherent in functional analysis of amplicons containing many overexpressed genes, our second specific aim is to develop new barcoded RNA library interference technology, which enables functional analysis of many genes in parallel, into a robust tool for functional analysis of amplicons with large numbers of candidate driver genes. Our results will produce new insights into the molecular basis of lung carcinogenesis and should identify key therapeutic targets and new strategies for diagnostics for this highly lethal cancer. The first goal of this study focuses on the discovery and functional characterization of novel causal genes of one of the most deadly forms of lung cancer. The second goal is to create a gene function-based tool to enable researchers to rapidly identify the causal gene within a recurrent amplified genomic region that contains too many genes to be studied by a gene-by-gene approach. Forward research progress of this research proposal is expected to positively impact the diagnosis and treatment of lung cancer in the future.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA127547-04
Application #
8113429
Study Section
Cancer Genetics Study Section (CG)
Program Officer
Mietz, Judy
Project Start
2008-09-08
Project End
2012-08-31
Budget Start
2011-08-01
Budget End
2012-08-31
Support Year
4
Fiscal Year
2011
Total Cost
$280,961
Indirect Cost
Name
Pennsylvania State University
Department
Pathology
Type
Schools of Medicine
DUNS #
129348186
City
Hershey
State
PA
Country
United States
Zip Code
17033
Wood, Lauren W; Cox, Nicole I; Phelps, Cody A et al. (2016) Thyroid Transcription Factor 1 Reprograms Angiogenic Activities of Secretome. Sci Rep 6:19857
Runkle, E Aaron; Mu, David (2013) Tight junction proteins: from barrier to tumorigenesis. Cancer Lett 337:41-8
Rice, Shawn J; Lai, Shao-Chiang; Wood, Lauren W et al. (2013) MicroRNA-33a mediates the regulation of high mobility group AT-hook 2 gene (HMGA2) by thyroid transcription factor 1 (TTF-1/NKX2-1). J Biol Chem 288:16348-60
Mu, David (2013) The complexity of thyroid transcription factor 1 with both pro- and anti-oncogenic activities. J Biol Chem 288:24992-5000
Runkle, E Aaron; Rice, Shawn J; Qi, Ji et al. (2012) Occludin is a direct target of thyroid transcription factor-1 (TTF-1/NKX2-1). J Biol Chem 287:28790-801
Conkrite, Karina; Sundby, Maggie; Mu, David et al. (2012) Cooperation between Rb and Arf in suppressing mouse retinoblastoma. J Clin Invest 122:1726-33
Qi, Ji; Mu, David (2012) MicroRNAs and lung cancers: from pathogenesis to clinical implications. Front Med 6:134-55
Qi, Ji; Rice, Shawn J; Salzberg, Anna C et al. (2012) MiR-365 regulates lung cancer and developmental gene thyroid transcription factor 1. Cell Cycle 11:177-86
Conkrite, Karina; Sundby, Maggie; Mukai, Shizuo et al. (2011) miR-17~92 cooperates with RB pathway mutations to promote retinoblastoma. Genes Dev 25:1734-45
Oliver, Trudy G; Mercer, Kim L; Sayles, Leanne C et al. (2010) Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. Genes Dev 24:837-52

Showing the most recent 10 out of 11 publications